IM
IMUX.US Immunic Inc
- Market cap
- USD 103M
- P/E
- -
- P/B
- 0.81x
- ROE
- -139.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IMUX.US undervalued?
Graham numberThe Graham number of Immunic Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immunic Inc fundamental analysis
No fundamental analysis for Immunic Inc yet.
Immunic Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical …
Full company profileImmunic Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Immunic Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 5.79K | -998K | -15.0K | -50.0K | -39.0K | -85.0K | -77.0K | -111K | -134K | -168K | - |
| Operating Income | -41.3M | -52.7M | -42.0M | -37.0M | -49.0M | -91.7M | -119M | -99.2M | -98.1M | -103M | -149M |
| EBITDA | -39.5M | -51.1M | -14.4M | -37.0M | -48.9M | -91.6M | -86.4M | -93.5M | -100M | -97.0M | -145M |
| Net Income | -41.0M | -52.1M | -41.5M | -34.8M | -44.0M | -92.8M | -120M | -93.6M | -101M | -97.2M | -145M |
| EPS | -522 | -523 | -490 | -45 | -28 | -39 | -38 | -21 | -10 | -6.24 | -3.40 |
| Balance Sheet | |||||||||||
| Total Assets | 64.0M | 60.4M | 15.0M | 66.0M | 168M | 139M | 128M | 54.3M | 40.9M | 24.1M | 136M |
| Total Liabilities | 5.58M | 10.3M | 2.55M | 7.59M | 9.08M | 12.0M | 14.1M | 25.4M | 22.4M | 30.7M | 32.0M |
| Shareholders' Equity | 58.4M | 50.0M | 12.4M | 58.4M | 159M | 127M | 114M | 28.9M | 18.4M | -6.67M | 104M |
| Cash & Short-term Investments | 60.0M | 56.9M | 13.3M | 29.4M | 127M | 86.9M | 116M | 46.7M | 35.7M | 15.5M | 132M |
| Total Debt | - | - | 37.2M | 520K | 976K | 992K | 1.56M | 1.33M | 1.00M | 684K | 503K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -35.8M | -40.4M | -43.2M | -28.5M | -46.1M | -83.2M | -65.1M | -70.8M | -84.8M | -85.8M | -102M |
| Capital Expenditure | 556K | 685K | 597K | 55.0K | 146K | 67.0K | 112K | 334K | 264K | 161K | 473K |
| Free Cash Flow | -36.3M | -41.1M | -43.8M | -28.6M | -46.3M | -83.3M | -65.3M | -71.2M | -85.0M | -86.0M | -103M |
| Ratios | |||||||||||
| ROE | -70.1% | -104.1% | -333.7% | -59.7% | -27.7% | -73.0% | -105.9% | -323.6% | -545.4% | - | -139.1% |
| ROA | -64.0% | -86.2% | -276.9% | -52.8% | -26.2% | -66.7% | -94.2% | -172.4% | -245.9% | -404.0% | -106.5% |
| Net Profit Margin | -682,816.7% | - | - | - | - | - | - | - | - | - | - |
| Debt to Equity | - | - | 2.99x | 0.01x | 0.01x | 0.01x | 0.01x | 0.05x | 0.05x | - | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Immunic Inc dividends
Immunic Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Apr 27, 2026.
Who owns Immunic Inc
- Insiders 2.18%
- Institutions 76.15%
- Public & others 21.67%
- Shares outstanding 13.6M
- Free float 12.0M
Top funds holding IMUX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| abrdn Healthcare Investors | 594K | 4.35% | +25.32% | Oct 2026 |
| abrdn Life Sciences Investors | 431K | 3.16% | +13.51% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 399K | 2.92% | 0.00% | Sep 2026 |
| abrdn World Healthcare | 117K | 0.86% | +145.61% | Sep 2026 |
| Fidelity Extended Market Index | 64.9K | 0.48% | -6.40% | Sep 2026 |
| iShares Micro-Cap ETF | 41.4K | 0.30% | 0.00% | Oct 2026 |
| Simplify Propel Opportunities ETF | 30.7K | 0.23% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 29.2K | 0.21% | -0.05% | Sep 2026 |
| Fidelity Series Total Market Index | 21.4K | 0.16% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 17.5K | 0.13% | 0.00% | Oct 2026 |
| ALPS Medical Breakthroughs ETF | 16.3K | 0.12% | 0.00% | Oct 2026 |
| Schwab Total Stock Market Index | 8.50K | 0.06% | 0.00% | Sep 2026 |
| Fidelity ZERO Total Market Index | 8.04K | 0.06% | 0.00% | Sep 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 7.41K | 0.05% | +1.93% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 7.13K | 0.05% | -21.98% | Aug 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 6.99K | 0.05% | 0.00% | Sep 2026 |
| China Universal Gbl YLBJ QDII CNH | 6.40K | 0.05% | 0.00% | Jun 2026 |
| Vanguard Balanced Index Inv | 6.23K | 0.05% | 0.00% | Sep 2026 |
| Fidelity ZERO Extended Market Index | 6.17K | 0.05% | +11.38% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 6.16K | 0.05% | 0.00% | Sep 2026 |
Top institutions holding IMUX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Aberdeen Group PLC | 1.09M | 7.99% | +32.27% | Sep 2026 |
| Bvf Inc | 765K | 5.61% | 0.00% | Jun 2026 |
| Millennium Management LLC | 740K | 5.43% | +95.86% | Jun 2026 |
| Avidity Partners Management LP | 670K | 4.91% | +900.00% | Jun 2026 |
| BRAIDWELL LP | 645K | 4.73% | 0.00% | Jun 2026 |
| LAURION CAPITAL MANAGEMENT LP | 610K | 4.47% | +57.21% | Jun 2026 |
| Vanguard Capital Management, LLC | 572K | 4.19% | +11.24% | Jun 2026 |
| Jones Hill Capital LP | 540K | 3.96% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 501K | 3.67% | +100.00% | Jun 2026 |
| Woodline Partners LP | 472K | 3.46% | +387.54% | Jun 2026 |
| Soleus Capital Management, L.P. | 450K | 3.30% | 0.00% | Jun 2026 |
| Propel Bio Management LLC | 325K | 2.38% | +38.62% | Jun 2026 |
| UBS Group AG | 176K | 1.29% | +236.18% | Jun 2026 |
| Geode Capital Management, LLC | 171K | 1.25% | +11.86% | Jun 2026 |
| Adage Capital Partners Gp LLC | 140K | 1.03% | 0.00% | Jun 2026 |
| BlackRock Inc | 133K | 0.97% | +37.72% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 105K | 0.77% | +9.99% | Jun 2026 |
| Susquehanna International Group, LLP | 90.9K | 0.67% | -11.61% | Jun 2026 |
| Jane Street Group LLC | 89.7K | 0.66% | +36.06% | Jun 2026 |
| Jefferies Financial Group Inc | 84.9K | 0.62% | 0.00% | Jun 2026 |
Immunic Inc company profile
- Company name
- Immunic Inc
- Ticker
- IMUX.US
- Exchange
- USA Stocks
- Listed since
- Apr 17, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Fiscal year end
- December
- Address
- 1200 Avenue of the Americas, New York, NY, United States, 10036
- Phone
- 332 255 9818
- Website
- imux.com
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Immunic Inc management
10- Mr. Jason Tardio M.B.A.COO & President · born 1977
- Mr. Glenn Whaley CPAChief Financial Officer · born 1968
- Mr. Erik LundgrenCEO & Director · born 1978
- Dr. Hella KohlhofCo-Founder & Chief Scientific Officer · born 1973
- Ms. Jessica BreuVice President of Investor Relations & Communications
- Mr. Inderpal SinghGeneral Counsel · born 1966
- Ms. Jaa RobersonChief People Officer
- Mr. Patrick WalshChief Business Officer · born 1983
- Mr. Werner GladdinesChief Development Officer · born 1979
- Dr. Michael A. Panzara M.D., M.P.H.Chief Medical Officer · born 1967